Collaboration is at the heart of our approach. We believe the bigger the challenge, the bigger the need for collaboration.
We are seeking partners across the life-science ecosystem — from pharmaceutical companies and investors to government agencies, contract research organizations, and academic institutions — to advance and commercialize our pipeline targeting the world's highest-priority resistant pathogens.
Work with us →
Fedora is open to a range of partnership structures across our anti-infective programs.
License a program or co-develop it with us toward the clinic and market.
Regional and global commercialization partnerships for our assets.
Equity and financing to accelerate development of the pipeline.
Government-supported development programs and non-dilutive funding.
Partnerships that advance our platform and discovery technologies.
Joint research with academic and industry partners on resistant pathogens.
Fedora's programs are positioned around urgent antimicrobial-resistance priorities, with relevance across biodefence, health-emergency preparedness, and vulnerable populations.
Addressing the disproportionate burden of drug-resistant infection in Canadian Indigenous communities.
Resistant infections are a leading threat to the wounded in conflict settings, where treatment options are scarce.
Effective antibiotics are critical national infrastructure and a matter of biodefence and health-emergency preparedness.
A portfolio of anti-infective programs at different stages of development.
| Program | Target / Indication | Stage | Partnering status |
|---|---|---|---|
| Nacubactam | Serious drug-resistant bacterial infections | Phase 3-ready | Available for partnership |
| FPI-2119 | Serious drug-resistant bacterial infections | Preclinical | Available for partnership |
| Other programs | To be disclosed | Discovery | Open to collaborate |
A rich pipeline of antibiotic and anti-infective programs with robust patent protection across all major markets.
Founded by a team whose contributions helped shape the modern treatment of resistant infections — with more than 100 years of cumulative global experience in anti-infective discovery and development.
Recognition at leading global conferences, contributions to the discovery of tazobactam, and the independent discovery of nacubactam — anticipated to enter the Japanese market.
Tell us a little about you and your area of interest, and the Fedora team will be in touch.
